Abstracts Archive - Page 1669 of 2607 - ACR Meeting Abstracts

Abstract Number: 1044 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Désirée van der Heijde², Xenofon Baraliakos³, Atul A. Deodhar⁴, Matt Brown⁵, Sarah Sherlock⁶, David Li⁷, Dona Fleishaker⁸ and Thijs Hendrikx⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor. Minimum clinically important differences (MCID) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI SI joint and spine…
Abstract Number: 1045 • 2016 ACR/ARHP Annual Meeting
2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis
Désirée van der Heijde¹, Sofia Ramiro², Robert Landewé³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Alexandre Sepriano², Andrea Regel⁶, John D. Reveille⁷ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: In 2010 the latest ASAS-EULAR recommendations for AS and the ASAS recommendations for the use of TNF-inhibitors (TNFi) have been published. Since then new…
Abstract Number: 1046 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures
Lars Rogge¹, Silvia Menegatti², Eleonora Latis¹, Elena Mascia¹, Hanane Yahia¹, Claire Leloup¹, Anna Molto³, Corinne Miceli-Richard⁴, Maxime Dougados^5,6 and Elisabetta Bianchi¹, ¹Immunology, Institut Pasteur, Paris, France, ²Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ³Hopital Cochin, Paris Descartes University, Paris, France, ⁴Rheumatology, Hôpital Cochin, Paris, France, ⁵Paris Descartes University, Paris, France, ⁶Service de Rhumatologie B, Hopital Cochin, Paris, France
Background/Purpose: The introduction of anti-TNF therapy has proven effective to reduce inflammation and clinical symptoms in several chronic inflammatory diseases. However, TNF-blockers are effective only…
Abstract Number: 1047 • 2016 ACR/ARHP Annual Meeting
Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
David Pisetsky¹, Dana Thompson¹, Joseph Wajdula², Annette Diehl² and Sudhakar Sridharan³, ¹Duke University Medical Center and Durham VAMC, Durham, NC, ²Global Product Development, Pfizer Inc, Collegeville, PA, ³PPD Inc, Rockville, MD
Background/Purpose: SLE clinical trials typically require that patients have either a positive ANA serology at a central laboratory during screening or have prior positive…
Abstract Number: 1048 • 2016 ACR/ARHP Annual Meeting
Differences in Clinical Manifestations of SLE Across Four Racial/Ethnic Groups: The California Lupus Surveillance Project (CLSP)
Ernest Maningding¹, Jinoos Yazdany², Laura Trupin², Chris Tonner³, Charles G. Helmick⁴ and Maria Dall'Era⁵, ¹Internal Medicine, Santa Clara Valley Medical Center, San Jose, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴CDC, Atlanta, GA, ⁵Division of Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The CLSP is a population-based registry of individuals with SLE residing in San Francisco County, California from 2007 – 2009. The registry has a…
Abstract Number: 1049 • 2016 ACR/ARHP Annual Meeting
High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE
Luis E C Andrade¹, Jan Damoiseaux², Minoru Satoh³, Edward K.L. Chan⁴, Mônica Prado⁵, Henrique Mariz⁶, Renan Agustinelli⁷ and Alessandra Dellavance⁸, ¹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Dept of Oral Biology, University of Florida, Gainesville, FL, ⁵Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ⁷Rheumatology Division, Escola Paulista de Medicina, São Paulo, Brazil, ⁸Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil
Background/Purpose: A positive ANA test is one of ACR Revised Criteria for Classification of SLE, as well as the SLICC classification. The ANA test provides…
Abstract Number: 1050 • 2016 ACR/ARHP Annual Meeting
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission is a desirable but not a common enough outcome in systemic lupus erythematosus (SLE) and therefore additional measures are needed to evaluate new…
Abstract Number: 1051 • 2016 ACR/ARHP Annual Meeting
Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)
Zahi Touma¹, Dafna D Gladman², Dorcas Beaton³, Jiandong Su⁴ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50) is a reliable and valid index able to measure ≥ 50% improvement in disease…
Abstract Number: 1052 • 2016 ACR/ARHP Annual Meeting
Longitudinal Patterns in SLE Response to Standard of Care Therapy: Implications for SLE Clinical Trial Design
Mimi Kim¹, Joan T Merrill², Kenneth Kalunian³, Bevra H. Hahn⁴, Anita Roach⁵, Peter M. Izmirly⁶ and the Lupus Foundation of America Collective Data Analysis Initiative Group., ¹Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ²OMRF, Oklahoma, OK, ³Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁴Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Education & Research, Lupus Foundation of America, Washington, DC, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Most clinical trials of new treatments for systemic lupus erythematosus (SLE) have shown weak discrimination between investigational agents and placebo when added to standard…
Abstract Number: 1053 • 2016 ACR/ARHP Annual Meeting
Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support
Melissa T. Flores¹, Jillian A. Rose², Priscilla Toral¹, Roberta Horton¹, Dariana M. Pichardo¹, Lillian Mendez¹ and Lisa F. Imundo³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Research shows that chronic illnesses such as SLE have multi-level impact on the family; it can be challenging for both patients & caregivers to…
Abstract Number: 1054 • 2016 ACR/ARHP Annual Meeting
Self-Reported Psychological Impact and Coping Strategies of Men with RA
Caroline Flurey¹, Sarah Hewlett², Karen Rodham³, Alan White⁴, Robert Noddings⁵ and John Kirwan⁶, ¹Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, ²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ³Psychology, Sport and Exercise, Staffordshire University, Stoke on Trent, United Kingdom, ⁴Centre for Men's Health, Leeds Beckett University, Leeds, United Kingdom, ⁵Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁶University of Bristol, Bristol, United Kingdom
Background/Purpose: Current RA research reflects the preponderance of women with the condition (30% male). Research in other conditions suggests men need their own health strategy.…
Abstract Number: 1055 • 2016 ACR/ARHP Annual Meeting
Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences
Nanna Maria Hammer¹, Julie Midtgaard², Merete Lund Hetland^3,4, Niels Steen Krogh⁵ and Bente Appel Esbensen^1,6, ¹Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, The DANBIO registry and Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²Section of Social Medicine, University of Copenhagen, Copenhagen, Denmark, Department of Public Health, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Zitelab, Frederiksberg, Denmark, ⁶Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark, Copenhagen, Denmark
Background/Purpose: While physical activity (PA) has been recommended as a part of the non-pharmacological management of inflammatory arthritis (IA), previous research within this area has…
Abstract Number: 1056 • 2016 ACR/ARHP Annual Meeting
Mind-Body Skills Training and Supportive Counseling for Depression in SLE: Positive Effects in a Randomized Controlled Trial
Carol Greco¹, Ling-Wan Chen², Yu Cheng³, Christine McFarland⁴ and Susan Manzi⁵, ¹Psychiatry, University of Pittsburgh, Pittsburgh, PA, ²Statistics, University of Pittsburgh, Pittsburgh, PA, ³Statistics and Psychiatry, UNIVERSITY OF PITTSBURGH, Pittsburgh, PA, ⁴Psychiatry, UNIVERSITY OF PITTSBURGH, Pittsburgh, PA, ⁵Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA
Background/Purpose: Although depressive symptoms are prevalent in persons with SLE, no studies to date have evaluated psychotherapy approaches in persons with SLE who also have…
Abstract Number: 1057 • 2016 ACR/ARHP Annual Meeting
Effect of Quantitative Information Concerning Medication Side-Effects on Risk Perception
Susan J. Blalock¹ and Matthew Dixon², ¹Eshelman School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC, ²Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, Namibia
Background/Purpose: The Food and Drug Administration (FDA) requires that patients prescribed a bisphosphonate to treat osteoporosis receive an FDA-approved Medication Guide that warns of the…
Abstract Number: 1058 • 2016 ACR/ARHP Annual Meeting
Adjustment Profiles Comprising Objective and Subjective Measures in Fibromyalgia Patients
Fernando Estévez-López^1,2, Inmaculada C Álvarez Gallardo¹, Víctor Segura-Jiménez^1,3, Milkana Borges-Cosic¹, Manuel Pulido-Martos⁴, Ana Carbonell-Baeza³, Virginia A Aparicio^1,5, Rinie Geenen² and Manuel Delgado-Fernández¹, ¹University of Granada, Granada, Spain, ²Utrecht University, Utrecht, Netherlands, ³University of Cádiz, Cádiz, Spain, ⁴University of Jaén, Jaén, Spain, ⁵VU University Medical Care, Amsterdam, Netherlands
Background/Purpose: Only one-third of FM patients obtain benefits after receiving one of the available therapy modalities. Insights into the heterogeneous picture of FM might improve…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].